In the England and Wales, in 2013, it was recommended by the National Institute for Health and Care Excellence (NICE) for use in patients with ER+ , human epidermal receptor-2-negative (HER2−) early advanced breast cancer, assessed on the basis of clinical algorithms to be at intermediate-risk of DR and who would benefit from additional prognostic information to help guide chemotherapy prescribing [6]. Here, ERBB2 is linked to breast carcinoma.